news
Researchers use algorithm to design articifical proteins for vaccines
Scientists have developed a method for designing artificial proteins that tell the immune system which antibodies to produce so could enhance vaccine design.
List view / Grid view
Biopharmaceuticals
news
Researchers develop promising MERS vaccine, with potential for COVID-19
A MERS vaccine, which uses RNA-based adjuvants, has demonstrated efficacy in non-human primates and is now being developed as a prophylactic for COVID-19.
news
Glycomimetics could prevent COVID-19 from infecting human cells
Glycomimetics, a novel class of antivirals, prevented influenza, herpes viruses and papillomaviruses from infecting cells in animal models and could show similar efficacy against COVID-19.
news
Plant bio-factories contributing to the COVID-19 fight
Researchers have made the genome of the Nicotiana benthamiana plant, a commonly used bio-factory organism, public to aid in COVID-19 vaccine production.
article
COVID-19 and big pharma: what are 15 leading companies doing to develop a coronavirus vaccine?
A new report has revealed the vaccine R&D efforts of 15 of the leading pharmaceutical companies to combat the COVID-19 coronavirus.
video
Video: Increased reproducibility with KingFisher™ instruments
ESHG 2019 Conference Presentation: Using KingFisher™ to increase reproducibility in new applications using challenging samples.
news
Collaboration to develop inhaled mRNA-based antibody therapy for COVID-19
Two companies, Neurimmune and Ethris, will leverage their technologies to research, develop and produce an inhaled therapy for COVID-19.
news
Cervical cancer cell-killing molecule manzamine A found in Indonesian sponge
A study has revealed that a sponge endemic to an Indonesian bay produces manzamine A, a compound which inhibits proteins in cervical cancers.
news
Novel COVID-19 vaccine shows efficacy in mice
Researchers have developed a vaccine against the COVID-19 coronavirus which induced the rapid production of antibodies in mice.
news
Decoy ACE2 receptors could be promising COVID-19 infection-preventing drug
Recombinant angiotensin converting enzymes (ACE2) reduced infection and viral growth in cell cultures and organoids by acting as a decoy for SARS-CoV-2.
article
How labs become AI ready with advanced informatics infrastructures
To reach the full potential of artificial intelligence (AI) in the pharma industry, it is essential that companies harmonise their data to remove the need for unnecessary human intervention. This article outlines how companies are working towards digital maturation and the obstacles they need to overcome to ensure the value…
article
The race to find a coronavirus treatment: are antibodies the answer?
At the beginning of March, US President Donald Trump pressed the pharmaceutical industry to “accelerate the development” of vaccines and therapies to contain the outbreak of the coronavirus pandemic. This article explores what is currently known about COVID-19 and potential treatments that are in the pipeline.
news
Artificial enzyme catalytic capabilities improved, say researchers
A study has shown that using a particular three-stranded structure can extend the catalytic performance of artificial metalloenzymes.
article
Rebalancing the immune system to treat autoimmune disease
Dr Nicolas Poirier reveals how immunotherapies can be designed to recalibrate the immune system for long-term maintenance of autoimmune remission.
article
Why invest in creating a modifiable drug framework?
Drug Target Review spoke with CUE Biopharma’s President and CSO to find out how and why they created the ImmunoSTAT platform and the ways it may benefit drug design in the future.
